EX-99.1 2 ea025231001ex99-1_relmada.htm PRESS RELEASE DATED AUGUST 7, 2025, REGARDING CORPORATE UPDATE AND SECOND QUARTER 2025 FINANCIAL RESULTS

Exhibit 99.1

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety

Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start

Phase III registration trial in 1H 2026

Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026

Conference Call and Webcast Today at 4:30 PM ET

CORAL GABLES, FL – Aug 7, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today reported financial results for the second quarter ended June 30, 2025, announced 6-month follow-up data from the Phase 2 study of NDV-01 in bladder cancer and provided a corporate and pipeline update.

Highlights of the 6-month follow-up data from the Phase 2 study of NDV-01:

Table 1: Baseline characteristics (n=29)
Gender | n (%)
Male | 24 (83%)
Female | 5 (17%)
Median Age (years) (range) | 73 (54-93)
Median BCG Doses (range) | 6 (0-18)
● BCG-naïve (n (%)) | 12 (41%)
● BCG exposed (n (%)) | 4 (14%)
● BCG unresponsive (n (%)) | 13 (45%)
Stage (n (%)) |
Pure CIS | 3 (10%)
Ta/T1 + CIS | 4 (14%)
Ta | 18 (62%)
T1 | 4 (14%)

Table 2: Clinical Results (Response Data)
Complete Response | % (n/N)
Anytime | 91% (21/23)
3 months | 83% (19/23)
6 months | 90% (19/21)

| ● | One subject has reached the 9-month assessment and had a complete response (CR)

| ● | No patient had progression to muscle invasive disease

| ● | No patient underwent a radical cystectomy

| ● | No patient had >= Grade 3 TRAE and no patients discontinued treatment due to AEs

“We are pleased to report that the six-month follow-up from the Phase 2 study of NDV-01, a gemcitabine/docetaxel (Gem/Doce) sustained release formulation, produced impressive results, with a 91% CR rate at any time point following NDV-01 treatment. The data reported today, in combination with the previously reported 3-month results, raise our confidence in NDV-01 as a potential durable treatment for bladder cancer,” said Raj S. Pruthi, MD, CMO of Relmada. “Gem/Doce have long shown clinical utility in non-muscle invasive bladder cancer (NMIBC), but the complexity of administration has limited their broader use. The sustained release formulation of NDV-01, which is designed to increase exposure to drug and simplify delivery and accessibility, has the potential to significantly change how we manage patients with NMIBC in routine practice.”

“As clinicians, we have embraced the combination of Gem/Doce as a highly effective therapy for many years,” said Yair Lotan, MD, Chair of Relmada’s Clinical Advisory Board. “However, it is difficult to formulate outside of the hospital setting, often creating a significant burden for patient and provider. NDV-01’s simple, ready-to-use sustained release formulation overcomes those burdens and could enable wider patient adoption transforming the care of NMIBC.”

Pipeline Highlights

NDV-01

A sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce)

| ● | Indication: High-Grade/Intermediate-Grade Non-Muscle Invasive Bladder Cancer (HG-NMIBC)

| ● | U.S. Market Opportunity: ~600,000 prevalent cases

| ● | Current Status: Phase 2 single-arm study actively enrolling

| ● | Next Steps:

| o | FDA interactions and product supply scale-up in 2H 2025

| o | Initiation of Phase 3 registration-track study in 1H 2026

2

Sepranolone

A first-in-class GABAA Modulating Steroid Antagonist (GAMSA)

| ● | Indications: Prader-Willi Syndrome (PWS), Tourette Syndrome (TS), Essential Tremor, and other compulsivity-related disorders

| ● | US Prevalence: Estimated 20,000 for PWS, an orphan disease

| ● | Current Status: Preparing for Phase 2 initiation in PWS

| ● | Next Steps:

| o | FDA engagement and manufacturing activities in 2H 2025

| o | Planned Phase 2 study launch in 1H 2026

Financial Results

Three Months Ended June 30, 2025 Results

| ● | R&D Expense: $2.8 million (vs. $10.7 million in Q2 2024), primarily associated with the wind-down of REL-1017 trial costs and lower stock-based compensation, partially offset an increase in R&D employee compensation expense

| ● | G&A Expense: $7.4 million (vs. $8.1 million), primarily due to lower stock-based compensation, partially offset by an increase in G&A employee compensation and consulting services expenses

| ● | Net Loss: $9.9 million or $0.30 per share (vs. $17.8 million or $0.59 per share)

Six Month Ended June 30, 2025 Results

| ● | R&D Expense: $14.7 million (vs. $24.0 million in 1H 2024), reflecting reduced REL-1017 trial costs and lower stock-based compensation, partially offset by an increase in costs associated with the NDV-01 and sepranolone acquisitions and an increase in R&D employee compensation expense

| ● | G&A Expense: $13.7 million (vs. $17.8 million in 1H 2024), primarily due to lower stock-based compensation and use of consulting services, partially offset by an increase in G&A employee compensation expense

| ● | Net Cash Used in Operations: $24.5 million (vs. $26.3 million)

| ● | Net Loss: $27.4 million or $0.86 per share (vs. $39.6 million or $1.31 per share)

| ● | Cash, Equivalents & Short-Term Investments: $20.6 million as of June 30, 2025 (vs. $44.9 million at year-end 2024)

| ● | Shares Outstanding: 33,191,622 as of August 4, 2025

Conference Call and Webcast

Relmada will host a conference call today, August 7, 2025, at 4:30 PM ET to discuss its Q2 2025 results and pipeline progress.

| ● | Dial-in (U.S.): 1-877-407-0792

| ● | Dial-in (International): 1-201-689-8263

| ● | Conference ID: 13754263

| ● | Webcast Access: Click Here

A replay of the webcast will be available on the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

3

About NDV-01

NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for the treatment of non-muscle invasive bladder cancer. It is designed to enable Gem/Doce bladder retention and gradual drug release over 10 days. The formulation creates a soft matrix that enhances local exposure while minimizing systemic toxicity. NDV-01 is convenient to administer in-office, in less than 10 minutes, and does not require anesthesia or specialized equipment. It is protected by patents through 2038.

About the Phase 2 Study

The Phase 2 study (NCT06663137) is an open-label, single-arm, single-center study evaluating the safety and efficacy of NDV-01 in patients with HG-NMIBC. Patients are treated with NDV-01 in a biweekly induction phase, follow by monthly maintenance for up to one year, with regular assessments via cystoscopy, cytology, and biopsy, as indicated. The primary efficacy endpoints are safety and complete response rate (CRR) at 12 months, and secondary efficacy endpoints are duration of response (DOR) and event free survival (EFS).

About NMIBC

NMIBC represents ~75% of all bladder cancer cases and is associated with high recurrence (50–75% over 7 years). With over 600,000 prevalent cases in the U.S. and limited treatment options,

the market opportunity is significant. NDV-01 has the potential to serve as a frontline or salvage therapy and could be applicable across multiple NMIBC subtypes.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABAA receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome, Tourette syndrome, and Obsessive-Compulsive Disorder (OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with an excellent safety profile.

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. US prevalence is estimated to be 20,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Lead candidates NDV-01 and sepranolone are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

4

Forward-Looking Statements:

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to progress, including the potential for Phase 2 NDV-01 data to continue to deliver positive results supporting further development, potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to secure FDA agreement on the regulatory path for NDV-01, and sepranolone, or that future NDV-01, or sepranolone, clinical results will be acceptable to the FDA, failure to secure adequate NDV-10, or sepranolone, drug supply, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications

media@relmada.com

5

Relmada Therapeutics, Inc.

Condensed Consolidated Balance Sheets

|  | As of |  |  |  |
|  | June 30, |  |  | As of |
|  | 2025 (Unaudited) |  |  | December 31, 2024 |
Assets |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 1,353,351 |  |  | $ | 3,857,026 |
Short-term investments |  |  | 19,266,190 |  |  |  | 41,052,356 |
Prepaid expenses |  |  | 474,628 |  |  |  | 886,461 |
Total current assets |  |  | 21,094,169 |  |  |  | 45,795,843 |
Other assets |  |  | 21,975 |  |  |  | 21,975 |
Total assets |  | $ | 21,116,144 |  |  | $ | 45,817,818 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,361,911 |  |  | $ | 4,130,563 |
Accrued expenses |  |  | 3,772,636 |  |  |  | 6,160,827 |
Total current liabilities |  |  | 5,134,547 |  |  |  | 10,291,390 |
Stock appreciation rights |  |  | 32,116 |  |  |  | 4,467 |
Total liabilities |  | $ | 5,166,663 |  |  | $ | 10,295,857 |
Stockholders’ Equity: |  |  |  |  |  |  |  |
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding |  |  | - |  |  |  | - |
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding |  |  | - |  |  |  | - |
Common stock, $0.001 par value, 150,000,000 shares authorized, 33,191,622 and 30,174,202 shares issued and outstanding, respectively |  | $ | 33,191 |  |  | $ | 30,174 |
Additional paid-in capital |  |  | 684,224,232 |  |  |  | 676,373,822 |
Accumulated deficit |  |  | (668,307,942 | ) |  |  | (640,882,035 | )
Total stockholders’ equity |  |  | 15,949,481 |  |  |  | 35,521,961 |
Total liabilities and stockholders’ equity |  | $ | 21,116,144 |  |  | $ | 45,817,818 |

6

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

|  | Three months ended |  |  | Six months ended |
|  | June 30, |  |  | June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  | $ | 2,819,377 |  |  | $ | 10,721,089 |  |  | $ | 14,770,400 |  |  | $ | 24,026,395 |
General and administrative |  |  | 7,401,929 |  |  |  | 8,097,695 |  |  |  | 13,669,342 |  |  |  | 17,780,249 |
Total operating expenses |  |  | 10,221,306 |  |  |  | 18,818,784 |  |  |  | 28,439,742 |  |  |  | 41,806,644 |
Loss from operations |  |  | (10,221,306 | ) |  |  | (18,818,784 | ) |  |  | (28,439,742 | ) |  |  | (41,806,644 | )
Other (expenses) income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest/investment income, net |  |  | 321,458 |  |  |  | 963,013 |  |  |  | 761,745 |  |  |  | 2,018,901 |
Realized (loss) gain on short-term investments |  |  | 47,203 |  |  |  | 133,114 |  |  |  | 110,156 |  |  |  | 186,247 |
Unrealized (loss) gain on short-term investments |  |  | (13,797 | ) |  |  | (45,465 | ) |  |  | 141,934 |  |  |  | 5,248 |
Total other income |  |  | 354,864 |  |  |  | 1,050,662 |  |  |  | 1,013,835 |  |  |  | 2,210,396 |
Net loss |  | $ | (9,866,442 | ) |  | $ | (17,768,122 | ) |  | $ | (27,425,907 | ) |  | $ | (39,596,248 | )
Loss per common share – basic and diluted |  | $ | (0.30 | ) |  | $ | (0.59 | ) |  | $ | (0.86 | ) |  | $ | (1.31 | )
Weighted average number of common shares outstanding – basic and diluted |  |  | 33,191,622 |  |  |  | 30,174,202 |  |  |  | 31,807,943 |  |  |  | 30,153,186 |

7

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(unaudited)

|  | Three and Six months ended June 30, 2025 |
|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Par Value |  |  | Capital |  |  | Deficit |  |  | Total |
Balance – December 31, 2024 |  |  | 30,174,202 |  |  | $ | 30,174 |  |  | $ | 676,373,822 |  |  | $ | (640,882,035 | ) |  | $ | 35,521,961 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 3,572,769 |  |  |  | - |  |  |  | 3,572,769 |
Issuance of Restricted Common Stock |  |  | 3,017,420 |  |  |  | 3,017 |  |  |  | 902,209 |  |  |  | - |  |  |  | 905,226 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (17,559,465 | ) |  |  | (17,559,465 | )
Balance – March 31, 2025 |  |  | 33,191,622 |  |  |  | 33,191 |  |  |  | 680,848,800 |  |  |  | (658,441,500 | ) |  |  | 22,440,491 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 3,448,453 |  |  |  | - |  |  |  | 3,448,453 |
ATM Expenses |  |  | - |  |  |  | - |  |  |  | (73,021 | ) |  |  | - |  |  |  | (73,021 | )
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (9,866,442 | ) |  |  | (9,866,442 | )
Balance – June 30, 2025 |  |  | 33,191,622 |  |  | $ | 33,191 |  |  | $ | 684,224,232 |  |  | $ | (668,307,942 | ) |  | $ | 15,949,481 |

|  | Three and Six months ended June 30, 2024 |
|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Par Value |  |  | Capital |  |  | Deficit |  |  | Total |
Balance – December 31, 2023 |  |  | 30,099,203 |  |  | $ | 30,099 |  |  | $ | 646,229,824 |  |  | $ | (560,902,681 | ) |  | $ | 85,357,242 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 8,295,468 |  |  |  | - |  |  |  | 8,295,468 |
Options exercised for common stock |  |  | 74,999 |  |  |  | 75 |  |  |  | 246,672 |  |  |  | - |  |  |  | 246,747 |
ATM Expenses |  |  | - |  |  |  | - |  |  |  | (25,000 | ) |  |  | - |  |  |  | (25,000 | )
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (21,828,126 | ) |  |  | (21,828,126 | )
Balance – March 31, 2024 |  |  | 30,174,202 |  |  |  | 30,174 |  |  |  | 654,746,964 |  |  |  | (582,730,807 | ) |  |  | 72,046,331 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 7,213,419 |  |  |  | - |  |  |  | 7,213,419 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (17,768,122 | ) |  |  | (17,768,122 | )
Balance – June 30, 2024 |  |  | 30,174,202 |  |  | $ | 30,174 |  |  | $ | 661,960,383 |  |  | $ | (600,498,929 | ) |  | $ | 61,491,628 |

8

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

|  | Six months ended June 30, |
|  | 2025 |  |  | 2024 |
Cash flows from operating activities |  |  |  |  |  |
Net loss |  | $ | (27,425,907 | ) |  | $ | (39,596,248 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 7,926,448 |  |  |  | 15,508,887 |
Realized (gain) on short-term investments |  |  | (110,156 | ) |  |  | (186,247 | )
Unrealized (gain) on short-term investments |  |  | (141,934 | ) |  |  | (5,248 | )
Change in operating assets and liabilities: |  |  |  |  |  |  |  |
Prepaid expenses and other assets |  |  | 411,834 |  |  |  | 637,035 |
Accounts payable |  |  | (2,768,652 | ) |  |  | 668,559 |
Accrued expenses |  |  | (2,388,191 | ) |  |  | (3,326,511 | )
Stock appreciation rights compensation |  |  | 27,649 |  |  |  | - |
Net cash (used in) operating activities |  |  | (24,468,909 | ) |  |  | (26,299,773 | )
Cash flows from investing activities |  |  |  |  |  |  |  |
Purchase of short-term investments |  |  | (809,375 | ) |  |  | (8,313,312 | )
Sale of short-term investments |  |  | 22,847,630 |  |  |  | 32,386,030 |
Net cash provided by investing activities |  |  | 22,038,255 |  |  |  | 24,072,718 |
Cash flows from financing activities |  |  |  |  |  |  |  |
Proceeds from options exercised for common stock |  |  | - |  |  |  | 246,747 |
ATM Expenses |  |  | (73,021 | ) |  |  | (25,000 | )
Net cash (used in)/provided by financing activities |  |  | (73,021 | ) |  |  | 221,747 |
Net (decrease)/increase in cash and cash equivalents |  |  | (2,503,675 | ) |  |  | (2,005,308 | )
Cash and cash equivalents at beginning of the period |  |  | 3,857,026 |  |  |  | 4,091,568 |
Cash and cash equivalents at end of the period |  | $ | 1,353,351 |  |  | $ | 2,086,260 |

9